Puma Biotechnology (PBYI) Long-Term Deferred Tax (2024 - 2026)

Puma Biotechnology (PBYI) has 3 years of Long-Term Deferred Tax data on file, last reported at $3.8 million in Q1 2026.

• Quarterly Long-Term Deferred Tax fell 45.87% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 45.87% YoY) and the FY2025 annual result came in at $3.8 million, down 45.87% from the prior year.
• Long-Term Deferred Tax steadied at $3.8 million in Q1 2026, from $3.8 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $7.1 million in Q4 2024 to a low of $3.8 million in Q4 2025.
• A 3-year average of $6.0 million and a median of $7.1 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The widest YoY moves for Long-Term Deferred Tax: up 45.87% in 2025, down 45.87% in 2025.
• Tracing PBYI's Long-Term Deferred Tax over 3 years: stood at $7.1 million in 2024, then slumped by 45.87% to $3.8 million in 2025, then changed by 0.0% to $3.8 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $3.8 million (Q1 2026), $3.8 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.